Chinook Therapeutics Stock Debt To Equity
| KDNYDelisted Stock | USD 39.25 0.20 0.51% |
Chinook Therapeutics fundamentals help investors to digest information that contributes to Chinook Therapeutics' financial success or failures. It also enables traders to predict the movement of Chinook Stock. The fundamental analysis module provides a way to measure Chinook Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Chinook Therapeutics stock.
Chinook |
Chinook Therapeutics Company Debt To Equity Analysis
Chinook Therapeutics' Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Current Chinook Therapeutics Debt To Equity | 0.08 % |
Most of Chinook Therapeutics' fundamental indicators, such as Debt To Equity, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Chinook Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
CompetitionAccording to the company disclosure, Chinook Therapeutics has a Debt To Equity of 0.082%. This is 99.85% lower than that of the Biotechnology sector and 99.58% lower than that of the Health Care industry. The debt to equity for all United States stocks is 99.83% higher than that of the company.
Chinook Debt To Equity Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Chinook Therapeutics' direct or indirect competition against its Debt To Equity to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Chinook Therapeutics could also be used in its relative valuation, which is a method of valuing Chinook Therapeutics by comparing valuation metrics of similar companies.Chinook Therapeutics is currently under evaluation in debt to equity category among its peers.
Chinook Fundamentals
| Return On Equity | -0.57 | |||
| Return On Asset | -0.27 | |||
| Operating Margin | (39.98) % | |||
| Current Valuation | 2.64 B | |||
| Shares Outstanding | 67.05 M | |||
| Shares Owned By Insiders | 2.19 % | |||
| Shares Owned By Institutions | 96.71 % | |||
| Number Of Shares Shorted | 2.88 M | |||
| Price To Book | 3.06 X | |||
| Price To Sales | 27.90 X | |||
| Revenue | 6.13 M | |||
| Gross Profit | (135.08 M) | |||
| EBITDA | (164.2 M) | |||
| Net Income | (187.87 M) | |||
| Cash And Equivalents | 362.61 M | |||
| Cash Per Share | 5.76 X | |||
| Total Debt | 39.44 M | |||
| Debt To Equity | 0.08 % | |||
| Current Ratio | 12.60 X | |||
| Book Value Per Share | 5.32 X | |||
| Cash Flow From Operations | (117.48 M) | |||
| Short Ratio | 3.43 X | |||
| Earnings Per Share | (3.24) X | |||
| Price To Earnings To Growth | (0.99) X | |||
| Target Price | 40.3 | |||
| Number Of Employees | 214 | |||
| Beta | 0.67 | |||
| Market Capitalization | 2.71 B | |||
| Total Asset | 574.08 M | |||
| Retained Earnings | (419.63 M) | |||
| Working Capital | 334.76 M | |||
| Z Score | 39.94 | |||
| Net Asset | 574.08 M |
About Chinook Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Chinook Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Chinook Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Chinook Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Correlation Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Other Consideration for investing in Chinook Stock
If you are still planning to invest in Chinook Therapeutics check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Chinook Therapeutics' history and understand the potential risks before investing.
| Idea Optimizer Use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Correlation Analysis Reduce portfolio risk simply by holding instruments which are not perfectly correlated | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Money Managers Screen money managers from public funds and ETFs managed around the world | |
| Financial Widgets Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm |